Overview
GLP-1 receptor agonists (GLP-1 RAs) — including semaglutide, liraglutide, dulaglutide, exenatide, albiglutide, and efpeglenatide — exert cardioprotection through an intricate web of direct myocardial, vascular, metabolic, and systemic mechanisms. The GLP-1 receptor (GLP-1R) is expressed in the heart, vasculature, kidneys, and central nervous system, enabling pleiotropic effects that extend far beyond glycaemic control. These mechanisms span receptor-level signal transduction, mitochondrial biology, inflammation, autonomic modulation, and haemodynamic regulation.
GLP-1R Structure & Cardiac Expression
The GLP-1 receptor is a class B G-protein coupled receptor (GPCR) with a large extracellular N-terminal domain that anchors the GLP-1 peptide. It is expressed in sinoatrial nodal cells, ventricular cardiomyocytes, coronary artery endothelial cells, smooth muscle cells, cardiac fibroblasts, and epicardial adipocytes — establishing the structural basis for direct cardiac action.
Upon agonist binding, conformational rearrangement of the seven transmembrane helices activates heterotrimeric Gαs proteins, initiating the canonical cAMP–PKA cascade. Simultaneously, GLP-1R couples to Gαi and Gαq in a context- and ligand-dependent manner, and recruits β-arrestins for GPCR internalization and biased signalling.
The EPAC (Exchange Protein Activated by cAMP) pathway, distinct from PKA, activates Rap1 GTPase → B-Raf → MEK → ERK1/2 signalling, contributing to cell survival, mitochondrial stabilisation, and modulation of Ca²⁺ handling independently of PKA.
NF-κB Suppression & Cytokine Modulation
GLP-1R activation via cAMP → PKA phosphorylates the NF-κB subunit p65 (RelA), preventing its nuclear translocation. Additionally, PKA activates IκB kinase (IKK) suppressor proteins, stabilising IκBα and trapping NF-κB in the cytoplasm. This suppresses transcription of TNF-α, IL-6, IL-1β, MCP-1, VCAM-1, and ICAM-1 in vascular endothelial cells, macrophages, and cardiomyocytes.
In macrophages and foam cells within atherosclerotic plaques, GLP-1 RAs shift macrophage polarisation from M1 (pro-inflammatory) toward M2 (anti-inflammatory/reparative) phenotype by reducing TLR4 signalling and NLRP3 inflammasome assembly. IL-1β secretion is blunted, which reduces downstream systemic inflammation and plaque vulnerability.
Oxidative Stress Reduction
GLP-1 RAs reduce reactive oxygen species (ROS) through multiple complementary pathways:
- PKA phosphorylates and inhibits NADPH oxidase (NOX2/NOX4), the primary enzymatic source of superoxide (O₂⁻) in cardiomyocytes and endothelium
- Upregulation of Nrf2/HO-1 axis: cAMP → PKA → Nrf2 nuclear translocation → ↑ HO-1, NQO1, glutamate-cysteine ligase (GCL) expression
- ↑ mitochondrial Mn-SOD (SOD2) and catalase expression via PGC-1α
- eNOS activation → ↑ NO bioavailability → scavenges O₂⁻, prevents peroxynitrite (ONOO⁻) formation
- Reduced oxidation of LDL and phospholipids within plaques → ↓ foam cell formation
- Preserved endothelial nitric oxide synthase (eNOS) coupling → maintained vascular tone
- Attenuated CaMKII oxidation → reduced arrhythmogenic Ca²⁺ leak from SR via RyR2
- Reduced oxidative post-translational modification of contractile proteins (troponin, myosin)
- Diminished lipid peroxidation product 4-HNE, which otherwise impairs mitochondrial respiration
Blood Pressure & Heart Rate Effects
GLP-1 RAs consistently reduce systolic blood pressure by 2–5 mmHg through: (1) direct vasodilatory effect via eNOS/NO in renal and systemic vasculature; (2) natriuretic effect — GLP-1R on renal proximal tubule → ↓ Na⁺/H⁺ exchanger 3 (NHE3) activity → ↑ urinary Na⁺ excretion → ↓ plasma volume; (3) reduced sympathetic nervous system activity via central GLP-1R in the nucleus tractus solitarius (NTS), hypothalamus, and area postrema.
A modest heart rate increase (2–5 bpm) occurs via direct SA node GLP-1R stimulation (cAMP↑ → ↑ If "funny current" via HCN4 channels) and reduced baroreceptor-mediated vagal tone due to BP lowering. This is generally well-tolerated and not associated with adverse cardiac outcomes.
Cardiac Remodelling Prevention
GLP-1 RAs attenuate pathological cardiac hypertrophy and fibrosis — hallmarks of heart failure progression — through several interlocking mechanisms:
- cAMP → PKA → phosphorylation of HDAC (class II) → nuclear export → de-repression of anti-hypertrophic genes (MEF2 targets)
- PI3K/Akt → mTORC1 regulation (bimodal: physiological vs pathological growth discrimination)
- Reduced Ang-II signalling — GLP-1 RAs downregulate AT₁R expression in cardiomyocytes
- ↓ calcineurin–NFAT pathway activation by improved Ca²⁺ handling
- ↓ TGF-β1 / Smad2/3 signalling in cardiac fibroblasts → ↓ collagen I/III synthesis, ↓ myofibroblast differentiation
- ↑ MMP activity / ↓ TIMP expression → improved extracellular matrix remodelling
- Reduced macrophage-to-fibroblast crosstalk via ↓ TGF-β, PDGF, and connective tissue growth factor (CTGF) secretion
- ↓ reactive interstitial fibrosis by reducing oxidative stress-mediated fibroblast activation
HFpEF vs HFrEF — Differential Effects
In HFpEF (preserved EF) — characterised by diastolic dysfunction, myocardial stiffness, and microvascular inflammation — GLP-1 RAs exert particular benefit through: ↓ epicardial adipose tissue inflammation, ↑ eNOS–cGMP–PKG signalling (restoring titin phosphorylation → ↓ passive stiffness), ↓ myocardial fibrosis, and improved lusitropy (relaxation). The STEP-HFpEF trial demonstrated semaglutide improved HF symptoms and exercise capacity in obese HFpEF patients.
In HFrEF (reduced EF) — characterised by cardiomyocyte loss, eccentric remodelling, and neurohormonal activation — GLP-1R agonism faces the challenge that GLP-1R expression is downregulated in severely failing myocardium. Despite this, systemic effects (↓ afterload, ↓ body weight, anti-inflammatory) remain beneficial, though LIVE-trial data with liraglutide in non-diabetic HFrEF showed no benefit in cardiac function, suggesting direct inotropic effects may be modest.
Ca²⁺ Handling & Arrhythmia Protection
Abnormal Ca²⁺ cycling is central to both contractile dysfunction and arrhythmogenesis in heart failure. GLP-1 RAs improve Ca²⁺ homeostasis through:
Simultaneously, PKA-mediated RyR2 phosphorylation (Ser2808) in physiological GLP-1 concentrations stabilises the channel in its closed state, preventing spontaneous Ca²⁺ sparks and waves that trigger delayed afterdepolarisations (DADs) and ventricular arrhythmias. ↓ Oxidative CaMKII activation further prevents RyR2 hyperphosphorylation at Ser2814.
At the sinoatrial node, GLP-1R → cAMP → ↑ HCN4 (If channel) open probability → mild ↑ heart rate variability (HRV) improvements and ↑ vagal responsiveness over long-term treatment, potentially reducing sudden cardiac death risk.
Class Effect vs Drug-Specific Differences
The cardiovascular benefit appears to be a class effect of GLP-1 RAs, as evidenced by multiple positive CVOTs across structurally distinct molecules. However, magnitude differs: human GLP-1 analogues (semaglutide, liraglutide) show numerically greater MACE reduction than exendin-4 analogues (exenatide, liraglutide). This may reflect structural homology — human-sequence analogues may better engage cardiac GLP-1R conformations or demonstrate more favourable tissue penetration.
The SELECT trial's demonstration of benefit in non-diabetic patients definitively establishes that glucose-independent mechanisms — particularly weight loss, anti-inflammation, eNOS activation, and direct cardiomyocyte effects — are sufficient for cardiovascular protection.
The cardioprotective effects of GLP-1 RAs arise from a multi-layered, hierarchically organised set of mechanisms: at the molecular level, cAMP–PKA–EPAC cascades suppress apoptosis, protect mitochondria, and improve Ca²⁺ cycling; at the cellular level, cardiomyocytes, endothelial cells, macrophages, and fibroblasts are all directly modulated; at the tissue level, vascular tone, plaque stability, cardiac structure, and fluid balance are improved; and at the systemic level, body weight reduction, improved glycaemia, and reduced sympathoadrenal activity further amplify cardiovascular benefit. The convergence of these effects — confirmed across multiple large cardiovascular outcome trials — establishes GLP-1 RAs as a cornerstone of cardioprotective pharmacotherapy in patients with obesity and cardiometabolic disease.